China Pharma (NYSE:CPHI) Stock Price Up 0.7% – Time to Buy?

China Pharma Holdings, Inc. (NYSE:CPHI) shares shot up 0.7% during trading on Monday . The stock traded as high as $0.7389 and last traded at $0.6990. 13,360 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 82,772 shares. The stock had previously closed at $0.6939.

China Pharma Stock Performance

The company has a market cap of $3.51 million, a P/E ratio of -1.23 and a beta of 1.17. The business has a 50 day moving average price of $1.30 and a two-hundred day moving average price of $1.55. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.26 and a current ratio of 0.79.

Institutional Investors Weigh In On China Pharma

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC raised its position in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,426 shares of the company’s stock after acquiring an additional 7,356 shares during the quarter. Citadel Advisors LLC owned approximately 0.93% of China Pharma worth $59,000 at the end of the most recent quarter.

About China Pharma

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.